Get the Stockscreener App
0.5663
1.14%
0.0064
After Hours:
.57
0.0037
+0.65%
Cytosorbents Corp stock is traded at $0.5663, with a volume of 108.75K.
It is up +1.14% in the last 24 hours and down -24.74% over the past month.
CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales and Distributors/strategic partners in United States, Germany and Other Countries. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.
See More
Previous Close:
$0.5599
Open:
$0.58
24h Volume:
108.75K
Relative Volume:
1.21
Market Cap:
$35.57M
Revenue:
$37.06M
Net Income/Loss:
$-8.20M
P/E Ratio:
-4.2483
EPS:
-0.1333
Net Cash Flow:
$-12.87M
1W Performance:
-18.61%
1M Performance:
-24.74%
6M Performance:
-39.37%
1Y Performance:
-43.37%
1-Day Range:
$0.532
$0.60
1-Week Range:
$0.4992
$0.6955
52-Week Range:
$0.4992
$1.39
Cytosorbents Corp Stock (CTSO) Company Profile
Name
Cytosorbents Corp
Sector
Industry
Phone
973-329-8885
Address
305 COLLEGE ROAD EAST, PRINCETON, NJ
Compare CTSO vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CTSO
Cytosorbents Corp
|
0.5663 | 35.16M | 37.06M | -8.20M | -12.87M | -0.1333 |
ABT
Abbott Laboratories
|
102.67 | 177.03B | 44.33B | 6.50B | 7.40B | 3.717 |
SYK
Stryker Corp
|
328.59 | 124.89B | 25.12B | 3.25B | 4.28B | 8.3984 |
MDT
Medtronic Plc
|
86.65 | 110.08B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
62.75 | 93.53B | 20.08B | 2.89B | 3.66B | 1.9391 |
EW
Edwards Lifesciences Corp
|
80.08 | 45.84B | 6.07B | 1.06B | 1.34B | 1.8063 |
Cytosorbents Corp Stock (CTSO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-07-23 | Initiated | B. Riley Securities | Buy |
| Oct-14-21 | Resumed | B. Riley Securities | Buy |
| Sep-17-20 | Initiated | Jefferies | Buy |
| Sep-01-20 | Initiated | SVB Leerink | Outperform |
| Aug-08-17 | Reiterated | Maxim Group | Buy |
| Oct-26-16 | Initiated | Aegis Capital | Buy |
| May-24-16 | Initiated | Maxim Group | Buy |
| Oct-29-15 | Upgrade | WBB Securities | Speculative Buy → Buy |
| May-12-15 | Reiterated | MLV & Co | Buy |
| Apr-01-15 | Reiterated | MLV & Co | Buy |
| Mar-05-15 | Initiated | MLV & Co | Buy |
| Feb-25-15 | Initiated | WBB Securities | Speculative Buy |
| Jan-27-15 | Reiterated | H.C. Wainwright | Buy |
View All
Cytosorbents Corp Stock (CTSO) Latest News
Cytosorbents 10-K: Revenue $37.1M, EPS not disclosed - TradingView
CytoSorbents (NASDAQ: CTSO) outlines global blood purification push and FDA path - Stock Titan
Cytosorbents’ Earnings Call Balances Progress and Risk - The Globe and Mail
Cytosorbents Corporation (NASDAQ:CTSO) Q4 2025 Earnings Call Transcript - Insider Monkey
CytoSorbents 2025 Financials: Q4 & Annual Revenue and Loss ReportNews and Statistics - IndexBox
Cytosorbents Corporation Q4 2025 Earnings Call Summary - Yahoo Finance
H.C. Wainwright reiterates CytoSorbents stock rating at Neutral By Investing.com - Investing.com Canada
H.C. Wainwright reiterates CytoSorbents stock rating at Neutral - Investing.com
CytoSorbents Reports 2025 Financial Results: Revenue Growth, Clinical Advances, and Path to Cash Flow Breakeven in 2026 - Minichart
CytoSorbents (CTSO) Reports Slight Revenue Increase and Strategi - gurufocus.com
CytoSorbents Corp (CTSO) Q4 2025 Earnings Call Highlights: Navigating Growth and Regulatory Challenges - gurufocus.com
Earnings call transcript: CytoSorbents reports Q4 2025 earnings miss, shares dip - Investing.com Australia
Cytosorbents Corp reports results for the quarter ended December 31Earnings Summary - TradingView
Cytosorbents (CTSO) Reports Record Sales Growth in 2025 - gurufocus.com
CytoSorbents Corp (NASDAQ:CTSO) Reports Q4 2025 Earnings Miss, Stock Declines - ChartMill
CytoSorbents: Q4 Earnings Snapshot - Barchart
CYTOSORBENTS ($CTSO) Releases Q4 2025 Earnings - quiverquant.com
CytoSorbents Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights - PR Newswire
Cytosorbents Corp expected to post a loss of 5 cents a shareEarnings Preview - TradingView
Cytosorbents (CTSO) Expected to Announce Earnings on Monday - Defense World
If You Invested $1,000 in Cytosorbents Corp (CTSO) - Stock Titan
CytoSorbents Announces HotSwap™ Launch, Renewed Aferetica Partnership, and New Clinical Evidence at ISICEM 2026 - Fidelity
Aug Drivers: How does Cytosorbents Corporation score in quality rankingsMarket Growth Summary & Safe Capital Growth Plans - baoquankhu1.vn
CytoSorbents Corp Stock (ISIN: US23283M1018) Faces Analyst Hold Amid Massive Upside Potential - AD HOC NEWS
Cytosorbents CorporationCommon Stock (Nasdaq:CTSO) Stock Quote - The Chronicle-Journal
CytoSorbents (CTSO) Stock Analysis Report | Ratings, Financials & Performance - Benzinga Japan
CTSO PE Ratio & Valuation, Is CTSO Overvalued - Intellectia AI
Aug Fed Impact: Will Cytosorbents Corporation benefit from government policy2025 Fundamental Recap & Reliable Breakout Stock Forecasts - baoquankhu1.vn
CytoSorbents to Report Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights - BioSpace
CTSO SEC FilingsCytosorbents Corp 10-K, 10-Q, 8-K Forms - Stock Titan
Latest CTSO NewsCytoSorbents Announces the REFRESH 2-AKI Tr... - Stock Titan
CTSO Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
CTSO.O PE Ratio & Valuation, Is CTSO.O Overvalued - Intellectia AI
Travel Stocks: What makes Cytosorbents Corporation stock attractive today2025 Top Decliners & Real-Time Price Movement Reports - baoquankhu1.vn
Head to Head: Cytosorbents vs. Futureworld - National Today
Investment Report: Can Brookfield Business Partners LP Limited Partnership keep up with sector leadersInsider Selling & Fast Gaining Stock Strategy Reports - baoquankhu1.vn
Analysts Expect Breakeven For Cytosorbents Corporation (NASDAQ:CTSO) Before Long - Yahoo Finance
Avenir reports 8.3% Cytosorbents (CTSO) ownership stake in 13G/A - Stock Titan
Aug Final Week: Is WaFd Inc stock undervalued right nowDay Trade & Reliable Price Breakout Alerts - baoquankhu1.vn
Aug PreEarnings: What makes Cytosorbents Corporation stock attractive today2025 Trade Ideas & Smart Allocation Stock Tips - baoquankhu1.vn
Rally Mode: Is Cytosorbents Corporation stock forming a cup and handleJuly 2025 Closing Moves & Trade Opportunity Analysis - baoquankhu1.vn
Trading Recap: What is CFBKs 5 year growth outlookQuarterly Risk Review & Safe Entry Point Identification - baoquankhu1.vn
Insider Buy: What is the earnings history of Cytosorbents CorporationMarket Sentiment Report & Weekly Chart Analysis and Guides - baoquankhu1.vn
CytoSorbents Reports Preliminary Unaudited Fourth Quarter and Full-Year 2025 Results and Business Update - BioSpace
CTSO Receives Continued 'Buy' Rating from D. Boral Capital | CTS - GuruFocus
CytoSorbents reports Q4 and full-year 2025 revenue expectations - Investing.com
CTSO Anticipates Improved Gross Margin for Full-Year - GuruFocus
Is Cytosorbents Corporation stock supported by strong fundamentalsMarket Growth Report & Verified Swing Trading Watchlists - ulpravda.ru
What hedge fund activity signals for Cytosorbents Corporation stockCEO Change & Comprehensive Market Scan Insights - ulpravda.ru
What is the fair value of Cytosorbents Corporation stock nowJuly 2025 Selloffs & Reliable Momentum Entry Alerts - ulpravda.ru
Reviewing Omeros (NASDAQ:OMER) and Cytosorbents (NASDAQ:CTSO) - Defense World
Cytosorbents Corp Stock (CTSO) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.03%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):